---
layout: default
title: Ipilimumab
description: "Ipilimumab çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 2 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 91
evidence_level: L5
indication_count: 2
---

# Ipilimumab

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>2</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Ipilimumab (æ˜“ä¹³è«å–®æŠ—) - è—¥å¸«è©•ä¼°å ±å‘Š

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Ipilimumab å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
æ˜“ä¹³è«å–®æŠ—æ˜¯ä¸€ç¨®æŠ— CTLA-4 å…ç–«æª¢æŸ¥é»æŠ‘åˆ¶åŠ‘ï¼ŒTxGNN é æ¸¬å…¶å°éçš®è†šé»‘è‰²ç´ ç˜¤æœ‰ç™‚æ•ˆï¼Œé€™é …é æ¸¬ç²å¾—å¤§é‡è‡¨åºŠè©¦é©—æ”¯æŒï¼Œå±•ç¾äº†æ¥µé«˜çš„è½‰è­¯åƒ¹å€¼ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©å­¸å | Ipilimumab |
| å°ç£å•†å“å | ç›Šä¼æ³¨å°„åŠ‘ 5 æ¯«å…‹/æ¯«å‡ (YERVOY) |
| DrugBank ID | DB06186 |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | ç„¡æ³•åˆ‡é™¤æˆ–è½‰ç§»æ€§é»‘è‰²ç´ ç˜¤ã€è…ç´°èƒç™Œã€NSCLCã€è‚ç´°èƒç™Œã€å¤§è…¸ç›´è…¸ç™Œã€é£Ÿé“ç™Œç­‰ï¼ˆå¤šèˆ‡ nivolumab ä½µç”¨ï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | metastatic melanomaã€choroideremia |
| æœ€é«˜è­‰æ“šç­‰ç´š | L1/L2 (å¤šé … RCT ç ”ç©¶) |
| å°ç£ä¸Šå¸‚ç‹€æ…‹ | æœ‰æ•ˆè¨±å¯è­‰ |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. choroideremia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.06%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Ipilimumab é€éé˜»æ–· CTLA-4 ä¾†å¢å¼· T ç´°èƒæ´»åŒ–ï¼Œè§£é™¤å…ç–«ç³»çµ±å°è…«ç˜¤çš„æŠ‘åˆ¶ï¼š

1. **éçš®è†šé»‘è‰²ç´ ç˜¤** (TxGNN Score: 0.990, Rank: 16733)ï¼š
   - åŒ…æ‹¬é»è†œé»‘è‰²ç´ ç˜¤ã€çœ¼éƒ¨é»‘è‰²ç´ ç˜¤ï¼ˆè‘¡è„è†œé»‘è‰²ç´ ç˜¤ï¼‰ç­‰
   - é€™äº›äºå‹è¼ƒçš®è†šé»‘è‰²ç´ ç˜¤å°‘è¦‹ï¼Œä½†å…·æœ‰ç›¸ä¼¼çš„å…ç–«åŸæ€§
   - Ipilimumabï¼ˆç‰¹åˆ¥æ˜¯èˆ‡ nivolumab ä½µç”¨ï¼‰å·²åœ¨é€™äº›äºå‹ä¸­é¡¯ç¤ºç™‚æ•ˆ

2. **è„ˆçµ¡è†œç„¡è™¹è†œç—‡ (Choroideremia)** (TxGNN Score: 0.991, Rank: 16090)ï¼š
   - é€™æ˜¯ä¸€ç¨®éºå‚³æ€§è¦–ç¶²è†œé€€åŒ–ç–¾ç—…ï¼Œéè…«ç˜¤æ€§
   - æ­¤é æ¸¬çš„æ©Ÿè½‰é—œè¯ä¸æ˜ï¼Œå¯èƒ½ç‚ºå½é™½æ€§

### è‡¨åºŠè©¦é©—

é‡å°ã€Œéçš®è†šé»‘è‰²ç´ ç˜¤ã€ï¼Œæª¢ç´¢åˆ°è¶…é **40 é …ç›¸é—œè‡¨åºŠè©¦é©—**ï¼š

### é‡é» Phase 3 è©¦é©—

| è©¦é©—ç·¨è™Ÿ | æ¨™é¡Œ | ç‹€æ…‹ | å…¥çµ„äººæ•¸ |
|----------|------|------|----------|
| NCT01844505 | Nivolumab å–®è—¥æˆ–ä½µç”¨ Ipilimumab vs Ipilimumab å–®è—¥ç”¨æ–¼æœªæ²»ç™‚è½‰ç§»æ€§é»‘è‰²ç´ ç˜¤ | å·²å®Œæˆ | 945 |
| NCT03469960 | Nivolumab-Ipilimumab æŒçºŒæ²»ç™‚ vs è§€å¯Ÿç”¨æ–¼ PD-L1 é™½æ€§ NSCLC | å·²å®Œæˆ | 265 |

### é‡é» Phase 2 è©¦é©—

| è©¦é©—ç·¨è™Ÿ | æ¨™é¡Œ | ç‹€æ…‹ | å…¥çµ„äººæ•¸ |
|----------|------|------|----------|
| NCT02626962 | Nivolumab + Ipilimumab ç”¨æ–¼æœªæ²»ç™‚è½‰ç§»æ€§è‘¡è„è†œé»‘è‰²ç´ ç˜¤ | å·²å®Œæˆ | 52 |
| NCT03999749 | Tocilizumab + Ipilimumab + Nivolumab ç”¨æ–¼æ™šæœŸé»‘è‰²ç´ ç˜¤ | é€²è¡Œä¸­ | 71 |
| NCT05428007 | Sarilumab + Ipilimumab + Nivolumab + Relatlimab ç”¨æ–¼é»‘è‰²ç´ ç˜¤ | æ‹›å‹Ÿä¸­ | 105 |

### ç‰¹æ®Šé»‘è‰²ç´ ç˜¤äºå‹è©¦é©—

| è©¦é©—ç·¨è™Ÿ | é»‘è‰²ç´ ç˜¤äºå‹ | ç‹€æ…‹ |
|----------|--------------|------|
| NCT05384496 | é»è†œé»‘è‰²ç´ ç˜¤ | æ‹›å‹Ÿä¸­ |
| NCT03220009 | é»è†œé»‘è‰²ç´ ç˜¤ï¼ˆè¡“å‰è¼”åŠ©ï¼‰ | å·²æ’¤å› |
| NCT06295159 | å±€éƒ¨å€åŸŸæ™šæœŸé»‘è‰²ç´ ç˜¤ | æ‹›å‹Ÿä¸­ |
| NCT06999980 | å¯åˆ‡é™¤æ™šæœŸé»‘è‰²ç´ ç˜¤å’Œé»è†œé»‘è‰²ç´ ç˜¤ | å°šæœªæ‹›å‹Ÿ |

**è­‰æ“šç­‰ç´šï¼šL1/L2** - æœ‰å¤šé … RCT å’Œå¤§é‡è‡¨åºŠè©¦é©—æ•¸æ“šæ”¯æŒã€‚

### ç›¸é—œæ–‡ç»

### éçš®è†šé»‘è‰²ç´ ç˜¤ç›¸é—œï¼ˆ5+ ç¯‡æ–‡ç»ï¼‰

1. **Alexander M et al. (2014)** - Medical Journal of Australia
   - è©•ä¼° ipilimumab ç”¨æ–¼çš®è†šã€è‘¡è„è†œå’Œé»è†œé»‘è‰²ç´ ç˜¤çš„ç™‚æ•ˆ
   - åŒ…å«ä¸åŒé»‘è‰²ç´ ç˜¤äºå‹çš„åæ‡‰ç‡åˆ†æ

2. **Trinh VA et al. (2018)** - Discovery Medicine
   - æŠ— PD-1 å–®æŠ—æ²»ç™‚æ™šæœŸé»‘è‰²ç´ ç˜¤çš„è‡¨åºŠæ›´æ–°
   - è¨è«–éçš®è†šäºå‹å’Œè…¦è½‰ç§»çš„æ²»ç™‚ç­–ç•¥

3. **Woo TE et al. (2023)** - Current Oncology
   - æ¯”è¼ƒå¹´è¼• vs å¹´é•·æ‚£è€…ä½¿ç”¨ ICI å–®è—¥æˆ–ä½µç”¨çš„ç™‚æ•ˆ
   - æ¶µè“‹å¤šç¨®é»‘è‰²ç´ ç˜¤äºå‹

4. **D'Aniello C et al. (2018)** - Current Cancer Drug Targets
   - é»‘è‰²ç´ ç˜¤è¼”åŠ©æ²»ç™‚ç¶œè¿°
   - è¨è«– ipilimumab åœ¨ä¸åŒäºå‹ä¸­çš„æ‡‰ç”¨

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. non-cutaneous melanoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.02%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.02%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

**æœ‰æ•ˆè¨±å¯è­‰ï¼š**

| è¨±å¯è­‰å­—è™Ÿ | å•†å“å | è¨±å¯è­‰æŒæœ‰è€… | æ•ˆæœŸ |
|------------|--------|--------------|------|
| è¡›éƒ¨èŒç–«è¼¸å­—ç¬¬000958è™Ÿ | ç›Šä¼æ³¨å°„åŠ‘ 5 æ¯«å…‹/æ¯«å‡ | å°ç£å¿…æ²»å¦¥æ–½è²´å¯¶ | 2029/08/18 |

**æ ¸å‡†é©æ‡‰ç—‡ï¼ˆèˆ‡ nivolumab ä½µç”¨ï¼‰ï¼š**
1. ç„¡æ³•åˆ‡é™¤æˆ–è½‰ç§»æ€§é»‘è‰²ç´ ç˜¤ï¼ˆ12 æ­²ä»¥ä¸Šï¼‰
2. æ™šæœŸè…ç´°èƒç™Œï¼ˆä¸­åº¦/é‡åº¦é¢¨éšªï¼‰
3. MSI-H/dMMR è½‰ç§»æ€§å¤§è…¸ç›´è…¸ç™Œ
4. è‚ç´°èƒç™Œï¼ˆç¬¬ä¸€ç·šå’Œ sorafenib å¤±æ•—å¾Œï¼‰
5. è½‰ç§»æ€§æˆ–å¾©ç™¼æ€§éå°ç´°èƒè‚ºç™Œ
6. æƒ¡æ€§è‚‹è†œé–“çš®ç˜¤
7. é£Ÿé“é±—ç‹€ç´°èƒç™Œ

## å®‰å…¨æ€§è€ƒé‡

### å…ç–«ç›¸é—œä¸è‰¯äº‹ä»¶ (irAEs)

Ipilimumab + Nivolumab ä½µç”¨ç™‚æ³•çš„ Grade 3-4 irAEs ç™¼ç”Ÿç‡ç´„ 50-60%ï¼š

| ä¸è‰¯åæ‡‰é¡å‹ | å¸¸è¦‹è¡¨ç¾ | ç®¡ç†é‡é» |
|--------------|----------|----------|
| è…¸ç‚ | è…¹ç€‰ã€è¡€ä¾¿ | å¯èƒ½éœ€ corticosteroids |
| è‚ç‚ | è½‰æ°¨é…¶å‡é«˜ | ç›£æ¸¬è‚åŠŸèƒ½ |
| çš®è†šç‚ | çš®ç–¹ã€æ”ç™¢ | å¤–ç”¨/å…¨èº«æ€§ steroids |
| å…§åˆ†æ³Œç—…è®Š | ç”²ç‹€è…º/è…ä¸Šè…ºåŠŸèƒ½ç•°å¸¸ | è·çˆ¾è’™è£œå…… |
| è‚ºç‚ | å‘¼å¸å›°é›£ã€å’³å—½ | åœè—¥ä¸¦çµ¦äºˆ steroids |
| è…¸ç©¿å­” | ç½•è¦‹ä½†è‡´å‘½ | ç·Šæ€¥å¤–ç§‘ä»‹å…¥ |

### ä¸»è¦è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| Corticosteroids | Moderate | å¯èƒ½é™ä½å…ç–«æ²»ç™‚æ•ˆæœ |
| Hydrocortisone | Moderate | ç”¨æ–¼ irAEs ç®¡ç†æ™‚éœ€æ¬Šè¡¡ |
| Dexamethasone | Moderate | åŒä¸Š |
| å…¶ä»–å…ç–«æŠ‘åˆ¶åŠ‘ | Moderate | å¯èƒ½å½±éŸ¿ç™‚æ•ˆ |

### ç‰¹æ®Šæ—ç¾¤
- **è‚åŠŸèƒ½ä¸å…¨**ï¼šè¼•åº¦è‚åŠŸèƒ½ä¸å…¨ä¸éœ€èª¿æ•´åŠ‘é‡
- **è…åŠŸèƒ½ä¸å…¨**ï¼šä¸éœ€èª¿æ•´åŠ‘é‡
- **å­•å©¦**ï¼šç¦ç”¨ï¼Œå¯èƒ½è‡´ç•¸
- **è€å¹´æ‚£è€…**ï¼šæ¯’æ€§å¯èƒ½å¢åŠ ï¼Œéœ€å¯†åˆ‡ç›£æ¸¬


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hepatic Insufficiency** ğŸŸ¡ Moderate
- Care should be exercised when using ipilimumab in patients with moderate (total bilirubin greater than 1.5 to 3 times the upper limit of normal [1.5 to 3 x ULN] and any AST) or severe (total bilirubin greater than 3 x ULN and any AST) liver dysfuncti...

**Pneumonia** ğŸŸ¡ Moderate
- Ipilimumab can cause immune-mediated pneumonitis.  Care should be exercised when using ipilimumab in patients with preexisting pulmonary impairment.  Ipilimumab should be withheld or permanently discontinued depending on severity of pneumonitis.

**Colitis** ğŸŸ¢ Minor
- Ipilimumab can cause immune-mediated colitis, which may be fatal.  CMV infection/reactivation has been reported in patients with corticosteroid-refractory immune-mediated colitis; repeating infectious workup should be considered in these patients to ...

**Dermatitis** ğŸŸ¢ Minor
- Ipilimumab can cause immune-mediated rash or dermatitis (including bullous and exfoliative dermatitis, Stevens-Johnson syndrome [SJS], toxic epidermal necrolysis [TEN], and drug rash with eosinophilia and systemic symptoms [DRESS]).  Topical emollien...

**Endocrine System Diseases** ğŸŸ¢ Minor
- Immune-mediated endocrinopathies, including severe to life-threatening cases, have occurred with ipilimumab therapy.  It is recommended to monitor for signs/symptoms that may be clinical manifestations of underlying immune-mediated adverse reactions....

*å¦æœ‰ 4 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬è©•ä¼°çµè«–

Ipilimumab å°éçš®è†šé»‘è‰²ç´ ç˜¤çš„é æ¸¬æ˜¯**é«˜åº¦æœ‰åƒ¹å€¼çš„ç™¼ç¾**ï¼š

1. **è‘¡è„è†œé»‘è‰²ç´ ç˜¤**ï¼šå·²æœ‰ Phase 2 è©¦é©—æ•¸æ“šï¼Œé¡¯ç¤ºèˆ‡ nivolumab ä½µç”¨çš„ç™‚æ•ˆ
2. **é»è†œé»‘è‰²ç´ ç˜¤**ï¼šå¤šé …é€²è¡Œä¸­çš„è‡¨åºŠè©¦é©—æ­£åœ¨è©•ä¼°
3. **è„ˆçµ¡è†œç„¡è™¹è†œç—‡**ï¼šæ­¤é æ¸¬ç¼ºä¹æ©Ÿè½‰æ”¯æŒï¼Œå¯èƒ½ç‚ºå½é™½æ€§

### è­‰æ“šç­‰ç´šç¸½çµ

| é æ¸¬é©æ‡‰ç—‡ | TxGNN Score | è­‰æ“šç­‰ç´š | è©•ä¼° |
|------------|-------------|----------|------|
| éçš®è†šé»‘è‰²ç´ ç˜¤ | 0.990 | **L1/L2** | å¤šé … RCT æ”¯æŒï¼Œæ¥µé«˜åƒ¹å€¼ |
| è„ˆçµ¡è†œç„¡è™¹è†œç—‡ | 0.991 | L5 | æ©Ÿè½‰ä¸æ˜ï¼Œå¯èƒ½å½é™½æ€§ |

### å»ºè­°

1. **éçš®è†šé»‘è‰²ç´ ç˜¤**ï¼š
   - **å¼·çƒˆå»ºè­°æŒçºŒè¿½è¹¤è‡¨åºŠè©¦é©—é€²å±•**
   - ç¾æœ‰ Phase 2 è©¦é©—ï¼ˆNCT02626962ï¼‰çµæœå·²ç™¼è¡¨
   - å¯ä½œç‚ºè‡¨åºŠæ±ºç­–åƒè€ƒ
   - éƒ¨åˆ†äºå‹å¯èƒ½å·²å¯åœ¨ä»¿å–®å¤–ä½¿ç”¨æ¢ä»¶ä¸‹æ‡‰ç”¨

2. **é©æ‡‰ç—‡æ“´å¢å»ºè­°**ï¼š
   - è‘¡è„è†œé»‘è‰²ç´ ç˜¤å’Œé»è†œé»‘è‰²ç´ ç˜¤çš„è­‰æ“šå·²ç›¸å°æˆç†Ÿ
   - å¯è€ƒæ…®å‘ TFDA æäº¤é©æ‡‰ç—‡æ“´å¢ç”³è«‹

3. **è‡¨åºŠæ‡‰ç”¨æ³¨æ„äº‹é …**ï¼š
   - éçš®è†šé»‘è‰²ç´ ç˜¤é å¾Œé€šå¸¸è¼ƒçš®è†šå‹å·®
   - éœ€è¬¹æ…è©•ä¼°ç—…æ‚£ç‹€æ³å’Œ irAEs é¢¨éšª
   - å»ºè­°åœ¨æœ‰å…ç–«æ²»ç™‚ç¶“é©—çš„ä¸­å¿ƒä½¿ç”¨

---

*å ±å‘Šç”Ÿæˆæ—¥æœŸï¼š2026-02-11*
*è³‡æ–™ä¾†æºï¼šTxGNN çŸ¥è­˜åœ–è­œé æ¸¬ã€ClinicalTrials.govã€PubMedã€å°ç£ FDA*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Buprenorphine]({{ "/drugs/buprenorphine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Famotidine]({{ "/drugs/famotidine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Loteprednol Etabonate]({{ "/drugs/loteprednol_etabonate/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ouabain]({{ "/drugs/ouabain/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Aspirin]({{ "/drugs/aspirin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Ipilimumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/ipilimumab/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_ipilimumab,
  title = {Ipilimumabè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/ipilimumab/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
